Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 1, 2002, Pages 12-23

  Petraitiene, R ^a   Petraitis, V ^a   Groll, A H ^a   Sein, T ^a   Schaufele, R L ^a   Francesconi, A ^a   Bacher, J ^a   Avila, N A ^a   Walsh, T J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; ECHINOCANDIN B; GALACTOMANNAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; FEMALE; LUNG ASPERGILLOSIS; LUNG INFARCTION; LUNG WEIGHT; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; SCORING SYSTEM;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODELS, ANIMAL; FEMALE; LUNG DISEASES, FUNGAL; MANNANS; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PEPTIDES; PEPTIDES, CYCLIC; RABBITS; TREATMENT OUTCOME;

EID: 0036135430     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.1.12-23.2002     Document Type: Article

References (57)

1. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
2. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
3. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
4. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates
5. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species
6. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
7. Pathogenesis of invasive pulmonary aspergillosis during persistent granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression
8. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus
9. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia
10. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
11. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus
12. Epidemiology of invasive fungal infections in bone marrow transplantation
13. Antibiotics that inhibit fungal cell wall development
14. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
15. Therapeutic outcome in invasive aspergillosis
16. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
17. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
18. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
19. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection
20. Amphotericin B: 30 Years of clinical experience
21. Update on antifungals targeted to the cell wall: Focus on beta-1,3-glucan synthase inhibitors
22. The fungal cell wall as a drug target
23. Treatment of histoplasmosis with MK-0991 (L-743,872)
24. Treatment of murine disseminated candidiasis with L-743,872
25. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
26. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits
27. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): A reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
28. Five-year-survey of invasive aspergillosis in a Paediatric Cancer Centre. Epidemiology, management and long-term survival
29. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
30. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
31. Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis
32. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
33. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis
34. Lipopeptide inhibitors of fungal glucan synthase
35. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase
36. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT
37. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991
38. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
39. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
40. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: Influence of assay conditions
41. Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors
42. Nosocomial pneumonia in patients having bone marrow transplant: Attributable mortality and risk factors
43. Invasive aspergillosis, disease spectrum, treatment practices, and outcomes
44. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
45. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
46. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis
47. Rat monoclonal antibodies against Aspergillus galactomannan
48. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
49. Sandwich enzyme-linked immunosorbent assay compared with pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients
50. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans
51. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
52. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy
53. New targets and delivery systems for antifungal therapy
54. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits
55. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations